Endometrial Cancer Education
Endometrial cancer treatment is evolving with immunotherapy-lenvatinib combinations, molecular classification driving adjuvant decisions, and new targeted approaches. Knowledge Med sessions put providers in the center of case-based simulations to build confidence in this changing landscape.
Non-promotional, independently reviewed sessions led by faculty from Johns Hopkins, Columbia, Mount Sinai, and other leading academic medical centers.
What Providers Navigate
Physicians managing endometrial cancer face evolving treatment decisions that interactive, independently reviewed education can help address.
- Applying molecular classification (POLE, MSI-H, p53) to treatment decisions
- Selecting patients for immune checkpoint inhibitor combinations
- Managing advanced and recurrent endometrial cancer
- Integrating HER2-targeted therapy in serous endometrial cancer
What Sessions Cover
Knowledge Med Endometrial Cancer sessions use interactive case simulations to address these topics and more.
- Molecular classification and its role in adjuvant therapy decisions
- Pembrolizumab-lenvatinib and dostarlimab in advanced endometrial cancer
- Immunotherapy in MSI-H/dMMR endometrial cancer
- Emerging treatment strategies for recurrent disease
Interactive Endometrial Cancer Sessions
Case Simulations
Work through realistic endometrial cancer patient cases with expert faculty, making treatment decisions at each stage.
Live Polling
See how your clinical decisions compare to peers in real time — revealing practice patterns and knowledge gaps.
Personalized Report
Receive a session summary with your individual responses, peer benchmarks, and key Endometrial Cancer clinical takeaways.
More Solid Tumor Sessions
Knowledge Med offers interactive sessions across many indications — these are just some of the areas we cover.
Metastatic Colorectal Cancer
mCRC — Biomarker-driven first-line therapy selection in mCRC
HER2-Positive Breast Cancer
HER2+ — First-line treatment selection in HER2+ metastatic breast cancer
Metastatic Breast Cancer
mBC — First-line endocrine-based therapy selection in HR+/HER2- mBC
Triple-Negative Breast Cancer
TNBC — Immunotherapy in first-line metastatic TNBC: patient selection and regimens
Join a Endometrial Cancer Session
Third-party, non-promotional endometrial cancer education led by faculty from leading academic medical centers. Case simulations. Live polling. Personalized insights.
Join a Session